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Abstract
Background and Aims: Mesenchymal stromal cells (MSCs) were shown to have immunomodulatory activity and have been
applied for treating immune-mediated disorders. We compared the homing and therapeutic action of cryopreserved
subcutaneous adipose tissue (AT-MSCs) and bone marrow-derived mesenchymal stromal cells (BM-MSCs) in rats with
trinitrobenzene sulfonic acid (TNBS)–induced colitis.
Methods: After colonoscopic detection of inflammation AT-MSCs or BM-MSCs were injected intraperitoneally. Colonoscopic
and histologic scores were obtained. Density of collagen fibres and apoptotic rates were evaluated. Cytokine levels were
measured in supernatants of colon explants. For cell migration studies MSCs and skin fibroblasts were labelled with Tc-99m
or CM-DiI and injected intraperitonealy or intravenously.
Results: Intraperitoneal injection of AT-MSCs or BM-MSCs reduced the endoscopic and histopathologic severity of colitis,
the collagen deposition, and the epithelial apoptosis. Levels of TNF-a and interleukin-1b decreased, while VEGF and TGF-b
did not change following cell-therapy. Scintigraphy showed that MSCs migrated towards the inflamed colon and the uptake
increased from 0.5 to 24 h. Tc-99m-MSCs injected intravenously distributed into various organs, but not the colon. Cm-DiI-
positive MSCs were detected throughout the colon wall 72 h after inoculation, predominantly in the submucosa and
muscular layer of inflamed areas.
Conclusions: Intraperitoneally injected cryopreserved MSCs home to and engraft into the inflamed colon and ameliorate
TNBS-colitis.
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Introduction
Inflammatory bowel disease (IBD) comprises a spectrum of
chronic and relapsing diseases including Crohn’s disease (CD) and
ulcerative colitis. CD is characterized by a background of mucosal
T-cell dysfunction, inflammatory cell infiltration, and abnormal
cytokine production leading to uncontrolled and persistent
intestinal transmural inflammation [1]. Although the aetiology of
CD remains unknown, there is evidence indicating the existence of
an abnormal immune response against the gut comensal
microbiota [2]. However, despite all recent scientific advances in
the study of IBD, available therapies for CD are still largely based
on non-specific immunosuppressive agents, and continue to have
limited efficacy with major concerns regarding safety issues [3].
Indeed, this illustrates the need for investigating new therapeutic
alternatives to dampen local inflammation, both effectively
modulating Th1-driven response and restoring the integrity of
the mucosal barrier.
Mesenchymal stromal cells (MSCs) are adult somatic cells that
reside in the stroma of solid organs and are considered as
precursors of non-haematopoietic connective tissues. MSCs have
been demonstrated to differentiate into cells of mesodermal
lineage such as bone, cartilage, and fat [4]. Recently, MSC have
been explored in regenerative medicine due not only to their
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33360differentiation potential but mostly to the capacity to improve the
repair of damaged tissues by secretion of biological active
molecules [5]. In addition MSCs are also capable of actions
such as inhibiting T-cell proliferation [6], inducing T-cell
apoptosis [7], and blocking dendritic cell maturation [8]. Because
of their low immunogenicity profile MSCs can be successfully
transplanted in diverse allogeneic and xenogeneic settings [9].
Recently, MSCs obtained from the subcutaneous adipose tissue
(AT-MSCs), with basically the same immunomodulatory prop-
erties as bone marrow mesenchymal stromal cells (BM-MSCs),
have risen as a new therapeutic perspective for cell-based
therapies [10,11].
Successful application of AT-MSCs has been reported recently
in experimental colitis [12–14]. Nevertheless, in view of the
different protocols utilized in those studies, the biological
mechanisms underlying the beneficial effect and immunoregula-
tory activity of MSCs are yet to be determined. Therefore, here we
investigated in vivo the potential therapeutic effect of non-
myeloabaltive transplantation of cryopreserved allogeneic AT-
and BM-MSCs in trinitrobenzene sulfonic acid (TNBS)-induced
colitis, an established experimental model of CD [15]. Follow-up
colonoscopic assessment of animals allowed us to confirm colitis
induction and to grade inflammation in live animals. Furthermore,
we also investigated recruitment to the intestinal mucosa of MSCs
upon different routes of administration.
Results
Characterization of MSCs from Subcutaneous Adipose
Tissue and Bone Marrow
AT- and BM-MSCs were flow-cytometrically characterized
(after 3 passages). AT- and BM-MSCs were positive for CD90 and
CD29, but negative for CD45, CD11b, and CD34 (Figure 1A–F),
indicating that no haematopoietic cells remained in the MSCs
suspension used in our experiments. Of note, the doubling time of
AT- and BM-MSCs remained unchanged (approximately 36–
40 hours) up to 7 passages, but their growth stopped at 14
passages.
Figure 1. Biological characterization of mesenchymal stromal cells. Phenotypic analysis of MSCs was carried out by flow cytometry, which
revealed that BM- and AT-MSCs expressed the cell markers CD90 (Thy-1) and CD29, but did not express lineage markers such as CD45, CD11b and
CD34 (A–F). Solid black lines show AT-MSC, dotted black lines show BM-MSC, and gray lines are isotype control. Functionally, MSCs have the capacity
to form different cell lineages. AT- (G–I) and BM- (J–K) MSCs were able to differentiate into adipocytes (H, K) and osteocytes (I, L). These cells were
used in subsequent experiments. Oil Red O (G–H, J–K) and Von Kossa (I, L) staining. Length bars represent 50 mm.
doi:10.1371/journal.pone.0033360.g001
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To examine the ability to differentiate into multilineage cells, of
AT- and BM-MSCs were cultured with the addition of lineage-
specific induction factors. Adipogenic differentiation was con-
firmed by Oil Red-O staining (Figure 1H, K). Osteogenic
differentiation was determined by extra cellular matrix calcifica-
tion detected by Von Kossa staining (Figure 1I, L).
Intraperitoneal Inoculation of MSCs Ameliorates
TNBS-Induced Colitis
We first investigated the potential therapeutic effect of MSCs on
the TNBS-induced colitis model, which displays a predominant
Th1-mediated immune response characterized by mononuclear
cells infiltration throughout the colon wall, similar to human CD
[15,16]. Animals exposed to TNBS developed an extensive and
severe colitis, characterized by diarrhoea, and accompanied by a
wasting syndrome with remarkable weight loss.
In order to assess the severity of experimental colitis survival
rates and changes in body weight were recorded. In regard to
survival rates, deaths were observed in rats with TNBS-induced
colitis, but none occurred in the AT-MSCs-treated animals. No
statistical significance was found comparing survival rates among
the different treatment groups (p=0.225) (Figure 2A). As
expected, body weight significantly decreased in TNBS-colitic
animals treated with vehicle (cells solvent), compared with control
rats (p,0.001). At days 7 and 11, weight loss in TNBS-induced
animals significantly decreased following the treatment with AT-
MSCs (p,0.03), and BM-MSCs (p,0.04), respectively, compared
to vehicle-treated rats. In fact, MSCs-treated animals regained
weight after day 4, in a slope comparable to the one observed for
the control group (Figure 2B).
Colonoscopy was utilized for assessing the severity of colitis and
for the detailed follow-up of mucosal changes after treatment. At
day 4, animals were submitted to colonoscopy in order to confirm
the presence and the severity of colitis individually. Dramatic
changes were detected in all TNBS-induced animals, which
displayed a fragile mucosa with intense hyperaemia, oedema,
bleeding, deep and coalescent ulcerations, and necrosis. Animals
were then assigned a group and treated thereafter with AT-MSCs,
BM-MSCs, or vehicle. At day 11, animals were again submitted to
colonoscopy. Among the colitic animals, colonoscopic evaluation
Figure 2. Effect of MSCs on the clinical and colonoscopic parameters of the colitis model. Survival did not differ significantly among
experimental groups. Of the TNBS-colitic animals, 2 treated with vehicle died on days 4 and 7, and 1 treated with BM-MSCs died on day 9. Survival
was analyzed by the Kaplan–Meier log-rank test (A). Following TNBS-induction, animals presented a progressive weight loss compared with controls
(*p,0.001). After receiving AT- or BM-MSCs, animals gradually regained weight, in contrast to vehicle-treated animals (**p,0.046; ***p,0.004) (B).
Colonoscopic imaging was obtained after colitis induction at day 4, and after MSCs administration at day 11. In control experiments, colonoscopy was
performed following intra-rectal saline enemas, and intraperitoneal administration of vehicle in TNBS-induced animals (C). Differences before and
after treatment were evaluated with the Wilcoxon matched-pair signed rank test. Values are mean6S.E.M. of 10 animals/group.
doi:10.1371/journal.pone.0033360.g002
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and BM-MSCs (p=0.04), compared with vehicle-treated animals
(Figure 2C and 2D).
Intraperitoneal Inoculation of MSCs Induces Mucosal
Healing in TNBS-Induced Colitis
Morphological changes of HE-stained intestinal sections were
predominantly seen in the distal colon of TNBS-induced animals.
TNBS-colitis was characterized by an intense cellular infiltration,
predominantly of mononuclear cells, compatible with a Th1-
mediated immune response. Analysis of intestinal sections revealed
an increase in the microscopic damage score in TNBS-treated
animals, compared with controls. Administration of MSCs
significantly reduced the inflammatory scores in TNBS-treated
animals (Figure 3A and 3B).
Collagen deposition in the colonic tissue was assessed by
staining fibres with phosphomolibidic acid picro-sirius red dye.
Collagen fibres were clearly disorganized in the injured colon,
being diffusely distributed throughout the colon wall. Computer-
assisted quantitative analysis of tissue sections showed that the
density of collagen fibres was higher in the injured colon of TNBS-
induced rats, and the injection of MSCs was able to significantly
decrease collagen deposition within the colon, at levels comparable
to the control group (Figure 3C and 3D).
In this TNBS-colitis model, a significant reduction in apoptotic
cells was observed in the epithelium of MSCs-treated colitic
animals compared to vehicle-treated TNBS-induced animals
(p#0.004). In the lamina propria compartment rates of
TUNEL-positive mononuclear cells were significantly higher in
animals treated with vehicle, BM-MSCs, and AT-MSCs com-
pared to controls (p#0.04). On the other hand, apoptotic rates in
the lamina propria were not significantly different comparing
MSCs- to vehicle-treated colitic animals (Figure 4A and 4B).
Intraperitoneal Inoculation of MSCs Reduces
Inflammatory Responses in TNBS-Induced Colitis
Next, we investigated whether the administration of MSCs
could affect the production of inflammatory mediators mechanis-
tically involved in intestinal inflammation. TNBS treatment
induced a ,2-fold increase in TNF-a levels in the colon, which
reduced significantly after the intraperitoneal administration of
MSCs, regardless of its source (p#0.02) (Figure 5A). Similarly,
Figure 3. Effect of MSCs on histological parameters and collagen deposition in the colon. Paraffin sections were stained with HE (A), and
phosphomolibidic acid-picrosirius red dye (C) (original magnification 6100). AT- or BM-MSC were administered intraperitoneally at day 4. In control
experiments, histological evaluation was performed following intraperitoneal administration of vehicle, and intra-rectal saline enemas. Colonic
samples were scored according to histological parameters described in materials and methods. Density of collagen fibres was determined by a
computerized image analysis system. Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent
ranges, of 10 animals/group. Differences were analyzed using ANOVA on ranks with Dunnett’s test (B, D).
doi:10.1371/journal.pone.0033360.g003
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administration (p#0.03) (Figure 5B). No significant difference was
observed in the effect of AT-MSCs compared with BM-MSCs.
Angiogenesis has been regarded as an important element in
IBD pathogenesis, and angiogenesis blockade was shown to
attenuate inflammation [17]. Therefore, we sought to determine
whether treatment with MSCs would affect VEGF production in
the inflamed colon of the model. TNBS induced a 3.5-fold
increase in VEGF production. Administration of MSCs irrespec-
tive of the origin (AT- or BM-derived) did not reduce significantly
VEGF production to levels observed in control animals
(Figure 5C).
TGF-b is a multifunctional cytokine capable of modulating
epithelial cell restoration during active inflammation, and also of
remodelling the extra cellular matrix following intestinal injury
[18]. Here, we show that TNBS induced a ,3-fold increase in
TGF-b production, but levels did not reduce significantly after
MSCs-treatment, independent of being AT- or BM-derived
(Figure 5D).
IL-10 is a regulatory cytokine known to act as anti-inflamma-
tory molecule, critical for tissue homeostasis [19]. In this study, we
observed a significant increase in IL-10 levels after TNBS-induced
animals have been treated with MSCs (Figure 5E).
Trafficking and Distribution of MSCs in vivo
Tc-99m labelled MSCs that were intraperitoneally administered
into the right lower quadrant, moved within the first 2 h towards
the opposite side of the abdomen of TNBS-induced animals, but
not in controls. Twenty-four hours later, labelled cells accumulat-
ed in the surgically removed distal colon of TNBS-induced
Figure 4. Effect of MSCs on apoptotic rates within the colon. Apoptotic cells were detected by the TUNEL assay. Photomicrographs of the
colon show representative samples of a control, and from TNBS-induced colitic animals treated with BM- and AT-MSCs, or vehicle, and an internal
negative control without TdT enzyme (original magnification 6100) (A). Percentages of apoptotic cells in the colonic epithelium and in the lamina
propria were analyzed in at least 10 different areas per tissue section. Epithelial values of control and MSCs-treated animals were lower compared to
vehicle-treated colitis (p,0.008). Lamina propria values of MSCs- or vehicle-treated animals were higher compared with the control group (p,0.04).
Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 10 animals/group.
Differences were analyzed using ANOVA on ranks with Dunnett’s test (B).
doi:10.1371/journal.pone.0033360.g004
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additional controls did not migrate significantly to the inflamed
colon (Figure 6A).
To evaluate possible differences in terms of the route of
administration, Tc-99m-labeled MSCs were also intravenously
administered to animals, through the right jugular vein.
As a result, labelled-MSCs rapidly accumulated in the lungs,
and also distributed to the kidneys and liver in all animals within
the first 2 hours. Twenty-four hours later, labelled cells were
predominantly detected in the liver and kidneys, in addition to the
spleen and bladder of all animals. No significant concentration of
labelled cells was detected in the colon topography (Figure 6B).
To evaluate in more detail the tissue distribution of intraper-
itoneal injected MSCs which migrated towards the inflamed colon,
we stained MSCs with a lipophilic fluorochrome, an indocarbo-
cyanine (Cm-DiI). Hence, Cm-DiI is well retained and provides a
greater and long-lasting stability and staining intensity compared
to most other fluorochromes or radioisotopes, including Tc-99m
[20]. The orange-red Cm-DiI-labeled MSCs were mainly
observed in the muscular layer and the submucosa, but also in
the lamina propria, predominantly in the bottom of crypts. AT-
MSCs consistently distributed throughout the colon wall, from the
peritoneum to the epithelial layer. On the other hand, BM-MSCs
characteristically concentrated at the peritoneal surface, muscular
layer and the submucosa. However, in control animals and in the
non-inflamed tissue such as the proximal colon, no labelled MSCs
were observed (Figure 7).
Discussion
Currently, approved therapies for IBD have limited efficacy and
side effects constitute a major concern from aminosalicylates and
corticosteroids, to the new biological agents [3]. Although the
pharmacological agents are still the mainstay of IBD treatment,
safety issues and elevated costs of prolonged therapy encourage the
search for alternative approaches. Here, we tested the therapeutic
Figure 5. Effect of MSCs on cytokine production in the inflamed colon. Colonic explants were cultured for 24 h at 37uC. After centrifugation,
supernatants were used for measurement of the concentration of cytokines by an ELISA method for rat TNF-a (A), IL-1b (B), VEGF (C), TGF-b (D), and
IL-10 (E), as described in Supplementary Materials. AT-, BM-MSC, and vehicle were administered to colitic animals, while control group did not receive
any treatment. Values are expressed as picogram of cytokine/mL of culture supernatant, and normalized by protein contents. Horizontal bars
represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 10 animals/group. Differences were
evaluated with the one-way ANOVA on ranks with Dunnett’s test.
doi:10.1371/journal.pone.0033360.g005
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TNBS-induced colitis, a murine experimental model of CD. Of
note, we compared different routes of administration and tested
the functionality and potential beneficial effects of cryopreserved
MSCs in experimental colitis. In respect of efficacy, both AT- and
BM-MSCs consistently stabilized the animals’ weight, while
lowering the colonoscopic and histologic scores in the experimen-
tal model compared with colitic animals, after one week of
treatment. In particular, we demonstrated that treatment with
MSCs reduces the amount of collagen deposition, the rate of
epithelial apoptosis, and the local production of proinflammatory
cytokines. In addition, we delineated for the first time MSCs
homing to inflammatory sites and the route-dependent differential
distribution and engraftment of MSCs within the colonic tissue.
Similar to previous reports, in this study we have isolated MSCs
from the subcutaneous adipose tissue and the bone marrow of
Wistar rats, exhibiting several characteristics such as multipotent
differentiation into different cell lineages, and the expression of
mesenchymal cell surface markers [21]. In particular, the high
rates of population doubling easily expanded ex vivo and the
preserved functional properties after thawing, would enable us to
use them in several clinical conditions suitable for cell-based
therapy.
A potential caveat to the effective implementation of MSC-
based therapy is the current inability to direct these cells to tissues
of interest. In this study, we focused on the cell trafficking and
tissue localization of exogenous MSCs delivered through different
routes of administration. Similar to a previous study [22], we also
demonstrated that intravenously administered MSCs rapidly
accumulate into the lungs or within the liver and other organs,
with no evidence of homing to the colon. In contrast, others have
shown that bone marrow derived MSCs differentiate into sub-
epithelial myofibroblasts in mice with TNBS-induced colitis
following intravenous administration of cells [23,24]. In another
study with murine dextran sulphate sodium (DSS)-induced colitis,
exogenous CD34-negative stem cells also migrated towards the
inflamed colon and differentiated into endothelial cells following
intravenous administration [25]. Discrepancies regarding homing
experiments may result from different details in each protocol,
including the number of cells and doses administered, the
confluence of MSCs prior to infusion [26], the passage number,
as MSCs have been shown to gain or loose surface receptors
during culture [27,28], and also the site of isolation, the properties
of the media, and the route or site of injection. Because
systemically administered MSCs did not reach the inflamed colon
and had no beneficial effect in our TNBS-colitis model, we sought
to investigate whether intraperitoneal administration would
facilitate the homing and potential anti-inflammatory actions of
MSCs with exactly the same characteristics. In rats with TNBS-
induced colitis, submucosally injected Y-chromosome-positive AT-
MSCs traced with FISH were detected under the basal
membrane, in the muscle layer, and in adipose tissue, compatible
with fibroblast-like or smooth muscle cell by immunohistochem-
istry [12]. Although even not injecting the cells in such a close
proximity with tissue injury, we could still clearly demonstrate
MSCs migration and infiltration into the inflamed colon,
predominantly in the muscular layer and the submucosa, but also
in the lamina propria and the subepithelial space of the mucosa.
This is in contrast with a previous report of BM-MSCs being
detected in the epithelium of the stomach and intestine [29], and
the thought that MSCs in bone marrow would possibly be more
primitive than AT-MSCs. Actually, our results support the
concept that AT-MSCs have at least the same potential to
migrate and engraft in the inflamed tissue, and probably to
Figure 6. Migration of intraperitoneally and intravenously administered MSCs in experimental animals. Tec-99m-labeled MSCs were
administered to animals and followed for 24 hours using a gamma-camera. Tec-99m-labeled MSCs were injected intraperitoneally in the right lower
abdominal quadrant, and migrated towards the inflamed colon on the contra-lateral left lower quadrant, but not to the non-inflamed colon of
controls. Skin fibroblasts used as additional controls did not migrate towards the inflamed colon (A). Tec-99m-labeled MSCs injected through the
jugular vein accumulated first into the lungs and then gradually migrated towards liver, spleen, kidneys, and bladder. After 24 hours, labelled cells
were barely detectable (B). Images are representative of 3 independent experiments. All animals are lying on their backs. Right (R); left (L).
doi:10.1371/journal.pone.0033360.g006
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Furthermore, this is the first report to show in detail the path of
intraperitoneal injected MSCs, migrating to inflamed sites,
accumulating at the peritoneal lining of the inflamed colon, and
passing through the whole intestinal wall towards the luminal side.
In respect of the anti-inflammatory actions of exogenous MSCs,
downregulation of the Th1-driven inflammatory responses has
been previously reported following treatment with human AT-
MSCs of DSS-colitis [14], and TNBS-colitis [13]. In fact,
proinflammatory cytokines of the Th1-type of immune response
such as TNF-a and IL-1b are known to be present in high levels in
CD [2] and in TNBS-colitis [16]. TNF-a is regarded as a crucial
molecule for the development of the inflammatory process of CD,
and the beneficial actions of anti-TNF-a agents reinforces the role
of TNF-a in the pathogenesis as well as a therapeutic target in CD
[30]. IL-1b is another proinflammatory cytokine of the Th1-type
of immune response also known to be involved in the immediate
innate immune responses to peptidoglycan products [31,32]. In
the present study, levels of both TNF-a and IL-1b decrease in
colitic animals treated with MSCs in accordance to the notion that
MSCs possess immunomodulatory effects [8,33]. Independently of
being considered as stem cells per se or of questions regarding the
ability to differentiate into specific cell lineages, the successful anti-
inflammatory action of MSCs may not require their sustained
engraftment in tissue. As it has been proposed before, it is likely
that immunomodulatory properties of MSCs may be mediated in
a paracrine fashion in vivo [34,35].
Previous investigations on the ability of MSCs to modulate the
immune system were based initially on the suppression of T-cell
effector functions upon coculture with MSCs [8,36]. In another
approach focused on the interaction of MSCs with leukocytes
suggested that MSCs can increase suppressor populations, such as
Foxp3
+ regulatory cells [37], with consequent increase in IL-10
production [38,39]. These findings have motivated the utilization
of MSCs in a number of preclinical and clinical diseases. In
experimental colitis, the use of MSCs have demonstrated
beneficial effect in down-regulating proinflammatory cytokines
and increasing regulatory T-cell populations [13,14]. In addition
to actions on regulatory T-cells, in an experimental model of sepsis
MSCs were shown to induce macrophage reprogramming into a
regulatory profile, with the ability to produce IL-10 [40]. In
agreement with this, we also showed an increase in IL-10
production following MSCs treatment.
Although the exact mechanisms underlying MSC-mediated
suppression of lymphocyte proliferation remain basically un-
known, it is possible that MSCs can accelerate apoptosis of active
inflammatory cells. In the intestinal mucosa, apoptosis constitutes
a critical mechanism exerting control over lamina propria
mononuclear cells and regulating immune responses [41]. In this
study, persistently elevated rates of apoptosis in the lamina propria
despite the remarkable mucosal healing may indicate continued
apoptosis induction as a possible immunosuppressive mechanism
of MSCs transplantation. However, in the epithelial compartment,
increased rates of apoptosis were shown to result in disruption of
the epithelial barrier, overexposing the gut to luminal antigens and
thus initiating the systemic inflammatory response in experimental
models of IBD [42,43]. In the present study, a dramatic reduction
of epithelial cell apoptosis in TNBS-colitis was also observed
following intraperitoneal injection of MSCs. These results are
consistent with previous studies indicating that TNF-a and IFN-c
regulate intestinal epithelial cells proliferation and apoptosis
[44,45], and suggest that exogenous MSCs target directly or
indirectly key effectors in colon inflammation.
Persistently high TGF-b levels could contribute for down-
regulating the immune response, but could also enhance intestinal
fibrosis in the TNBS-model. Here, we showed that MSCs-
treatment of TNBS-colitis did not change the levels of TGF-b, but
significantly reduced collagen deposition. A possible explanation
for this effect could be attributed to the complex interaction
among the different mediators present in the context of colitis. For
example, TNF-a present in high levels in CD intestinal mucosa,
stimulate the production of metalloproteinases and collagen by
myofibroblasts and fibroblasts, contributing to matrix degradation
and fibrosis [46]. Therefore, it is likely that the immunomodula-
tory actions of MSCs, including TNF-a suppression could actually
Figure 7. Distribution and engraftment of intraperitoneally
administered MSCs in the colon. Cm-DiI-labelled MSCs (red)
injected intraperitoneally in the right lower abdominal quadrant were
tracked after 72 hours. After surgical removal of the distal colon,
samples were cut in a cryostat, counterstained with DAPI (blue), and
analyzed under confocal microscopy. Labelled cells migrated towards
the inflamed colon on the contra-lateral left lower quadrant, but not to
the non-inflamed colon of normal controls. Cm-DiI-labeled MSCs were
mainly observed in the muscular layer and the submucosa (SM), but
also in the lamina propria of the mucosa (M), predominantly in the
bottom of crypts. AT-MSCs distributed throughout the colon wall, from
the peritoneum to the epithelial layer, whereas BM-MSCs concentrated
at the peritoneal surface, muscular layer and the submucosa. No
labelled MSCs were observed in control animals. Intestinal lumen (L).
Images are representative of 3 independent experiments. Length bars
represent 100 mm.
doi:10.1371/journal.pone.0033360.g007
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TNBS-colitis model. In analogy, MSCs transplantation has been
shown to limit fibrosis of myocardial infarction and dilated
cardiomyopathy [47], which has been attributed to adrenome-
dullin, regarded as an antifibrotic factor secreted by MSCs [32].
The formation of new blood vessels is a critical step in wound
healing process [48]. Previously, it has been demonstrated that
BM-MSCs-treated wounds resulted in augmented capillary
density, an effect promoted by conditioned medium, suggesting
a paracrine effect of BM-MSCs, which also expressed high levels
of VEGF and Angiopoetin-1 [49]. Recent studies provided
evidence for the involvement of angiogenesis in the pathogenesis
of IBD. The expression of the proangiogenic factor VEGF was
shown to be increased in intestinal mucosa of patients with active
CD [17]. Corroborating literature data, here we showed a marked
increase of VEGF levels in the inflamed colon following TNBS
exposure. Administration of MSCs did not reduce significantly the
growth factor levels to that of control animals, suggesting that the
anti-inflammatory actions are independent of VEGF, which in
turn could promote and sustain angiogenesis in the model [50].
In conclusion, the successful treatment of experimental colitis
with the intraperitoneal administration of cryopreserved allogeneic
MSCs supports the idea of using these cells for treating intestinal
inflammation. In particular, considering that cells share the same
therapeutic properties, the use of AT-MSCs appears to be more
convenient than BM-MSCs because of ease and safety of isolation
by liposuction and the abundant tissue source of AT-MSCs. In
addition, the rapid ex vivo expansion and the possibility of
cryopreservation render these AT-MSCs a useful source for cell
therapy, emerging as a potential new alternative of non-
myeloabaltive cell-based therapy for human IBD.
Materials and Methods
Ethics Statement
The institutional animal care committee of the Federal
University of Rio de Janeiro approved the care and use of
animals, as well as procedures reported in this study (approval
number # 66/08), in accordance with the guidelines of the
International Care and Use Committee of the National Institutes
of Health, and Guide for the Care and Use of Laboratory Animals
(National Research Council-USA, 1996).
Animals
Male Wistar rats (each weighing between 250 and 300 g)
obtained from the Animal Care of the Laboratory of Experimental
Surgery of the Federal University of Rio de Janeiro (Rio de
Janeiro, RJ, Brazil) were maintained under specific pathogen-free
conditions in a temperature-controlled room (24uC), on a 12-h/
12-h light and dark cycle. Standard laboratory pelleted formula
and tap water were provided ad libitum. Animals were housed in
rack-mounted wire cages with 2 animals per cage.
Mesenchymal Stromal Cells Isolation and Culture
Bone marrow cell suspensions were obtained by flushing marrow
cavity of rats with Dulbecco’s modified Eagle medium-low glucose
(DMEM) (LGC Biotecnologia, Sa ˜o Paulo, SP, Brazil). Cells were
plated in 25 cm
2 culture flasks with DMEM supplemented with
15% Foetal Bovine Serum (Cultilab, Campinas, SP, Brazil) and
antibiotics (100 U/mL of sodium-penicillin and 100 mg/mL of
Streptomycin, both from Sigma-Aldrich, St. Louis, MO, USA).
After 2 to 3 days in culture, the non-adherent cells were removed
and adherent cells were maintained in culture until they reach 70%
confluence. The monolayer was trypsinized and expanded. AT-
MSCs were obtained as previously described [51]. Briefly,
subcutaneous inguinal adipose tissue was removed, dissected from
visible blood vessels, and enzimatically digested at 37uC in DMEM
with 2 mg/mL of collagenase type II (Sigma-Aldrich, MO, USA).
Cellsuspensionswerecentrifuged,and thepellet wasresuspended in
DMEMwith20%FBSand antibiotics,andfiltered innylonmesh of
100 mm. Cells were then plated in 25 cm
2 culture flasks and
incubated overnight at 37uC with 5% CO2. The non-adherent cells
were removed and the plastic-adherent cell population was
maintained and expanded as described above. After the third
passage MSCs were then stored in liquid nitrogen until being used
in the experiments. For this purpose, cryopreserved cells were first
thawed, washed twice and resuspended in phosphate buffered saline
(PBS) 0.1% bovine serum albumin (BSA) (vehicle).
Osteogenic Differentiation
Osteogenic differentiation was induced by adding to pre-
confluent monolayers DMEM supplemented with 10% FBS,
50 mM ascorbic acid, 10 mM b-glycerophosphate, 10
28 M
dexamethasone and antibiotics (all from Sigma-Aldrich Inc., St.
Louis, MO, USA). Cells were maintained in osteoinductive
medium containing dexamethasone for 1 week with alternate
day media exchange. After this period, dexamethasone was
removed and the cells were maintained as described above for
additional 2 weeks with alternate day media exchange. Calcium
deposition was revealed by Von Kossa staining [52].
Adipogenic Differentiation
To induce adipogenic differentiation, cells were cultured for 2
weeks with DMEM supplemented with 10% FBS, 10
28 M
dexamethasone, 100 mM indomethacin, (all from Sigma-Aldrich
Inc., St. Louis, MO, USA) and 2.5 mM insulin (BiohulinH, Biobra ´s
S.A., M. Claros, MG, Brazil). Cytoplasmic lipid deposits were
stained with Oil Red O solution (0.5% in isopropanol) for
20 minutes at room temperature. Cultures were counterstained
with Harris’ haematoxylin.
Flow Cytometry
Cell suspensions were washed with PBS with 3% FBS and 0.1%
sodium azide (staining buffer) and incubated for 30 min at 4uC with
fluorescein (FITC), R-phycoerythrin (R-PE), or Cychrome 5 (Cy5)
conjugated monoclonal mouse anti-rat antibodies, CD11b (Mac-1,
clone OX-42) from CaltagTM Lab (Invitrogen Life technologies,
USA), CD34 (clone ICO115) from Santa Cruz Biotechnology Inc.
(SantaCruz, CA,USA),CD29 (cloneHa 2/5), CD45 (clone OX-1),
and CD90 (clone OX-7), all from BD-Pharmingen (San Jose, CA,
USA). Cells were washed with the staining buffer and acquisition
was performed on a FACSCalibur using the CellQuest Pro software
(BD Biosciences, San Jose, CA, USA).
Skin Fibroblast Isolation and Culture
Skin fibroblasts were obtained by skin explants outgrowth. The
skin was shaved and cleaned, and the subcutaneous tissue was
removed. Skin fragments of 1 to 2 mm
2 were plated in 2 ml of
DMEM supplemented with 10% FBS and antibiotics. Cultures
were incubated overnight upside down. After this period the flasks
were carefully turned and fresh medium was added. Cultures were
maintained and expanded as described above.
Induction of Colitis
On day 0, rats were anesthetized subcutaneously with ketamine
(35 mg/kg) and xylazine (5 mg/kg), and colitis was induced by
intracolonic instillation of 1 ml of a solution containing 25 mg of
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St. Louis, MO, USA) in 30% ethanol (Merck, Darmstadt,
Germany) using a 4-French catheter (8-cm long) inserted through
the rectum, as previously described [53]. Thereafter, animals were
allowed access to standard chow and water ad libitum.
Experimental Design
After an acclimation period of one week, rats maintained under
specific pathogen-free conditions were randomly assigned to one of
four groups of 9–12 animals each. On day 0, colitis was induced by
the TNBS/ethanol administration. Rats receiving intracolonic
injection of phosphate buffered saline constituted the normal
control group. During the whole experiment clinical manifesta-
tions such as diarrhoea, bleeding, and weight changes were
recorded. On day 4, rats were anesthetized as described in the
previous paragraph and submitted to colonoscopy. Animals with
established colitis received AT-MSCs, BM-MSCs, or the cells’
vehicle. Because the effects of 0.5 and 1610
6 cells were only
modest in our preliminary experiments, we established 2610
6 cells
as the number of cells to be used in all experiments thereafter.
MSCs (2610
6 cells/0.3 mL) were administered in a single
intraperitoneal injection on day 4. On day 11, a follow-up
colonoscopy was performed, prior to tissue collection. For the
surgical procedure, animals were anesthetized as previously
described and submitted to a laparotomy under sterile technique.
The distal colon was removed, opened longitudinally, rinsed with
saline, and tissue samples were excised for histological assessment.
A quick death procedure by cervical dislocation was uniformly
performed in all animals on experimental day 11.
Colonoscopic Assessment
On experimental days 4 and 11, animals were anesthetized and
examined with a flexible fiberscope FB 120P with a diameter of
2.8 mm (Fujinon) assembled to a video-camera for recording
images. Colon injury was scored by two independent observers
using an adapted endoscopic index of colitis [54,55]. The following
parameters were analyzed and graded as 0 (absent) or 1 (present)
each: changes of the vascular pattern; mucosal granularity;
strictures; bleeding; and ulcers (total score ranging from 0–5).
Histological Inflammatory Scores of the Colon
Specimens were fixed in 40 g/liter formaldehyde saline,
embedded in paraffin, cut into 5-mm sections, stained with
haematoxylin-eosin stain, and examined microscopically by two
independent observers. The following histological parameters were
studied: ulceration, hyperplasia, and inflammatory infiltrate. For
both inflammatory infiltrate and hyperplasia, grading was consid-
ered: 3, severe; 2, moderate; 1, mild; 0, absent. For ulcers, grading
was: 4, diffuse glandular disruption or extensive deep ulceration; 3,
glandular disruption or focal deep ulceration; 2, diffuse superficial
ulceration; 1, focal superficial ulceration; and 0, absent [56].
Assessment of Collagen Deposition in the Colon
Specimens were fixed in 40 g/litre formaldehyde saline,
embedded in paraffin, and cut into 5-mm sections. The
phosphomolibidic acid picro-sirius red dye was used to stain
collagen fibres in tissue [57]. At least 10 different areas per tissue
section were analyzed under light microscopy connected to a
computer-assisted image analyzer.
Assessment of Apoptosis in the Colon
To determine apoptosis, fragmented DNA was stained by the
terminal deoxynucleotidyltransferase (TdT)-mediated dUDP-bio-
tin nick end labelling (TUNEL) assay, with the TACS TM TdT kit
- in situ apoptosis detection kit (R&D Systems, Minneapolis, MN,
USA). Paraffin sections were first deparaffinized, incubated with
proteinase K solution for 15 minutes at room temperature, and
then immersed in hydrogen peroxide to block endogenous
peroxidase activity. After rinsing, slides were incubated with the
TdT labelling buffer for 5 minutes. This step was followed by the
incubation with the labelling reaction Mix containing TdT
enzyme for 1 hour at 37uC. The biotinylated nucleotides
incorporated to DNA fragments were detected using streptavidin
horseradish peroxidase conjugate. A second section of each
sample, incubated without TdT enzyme, constituted the negative
controls. Positive controls were prepared by treating samples with
TACS-nuclease. After being rinsed in PBS, all sections were
developed with a solution containing hydrogen peroxide and
diaminobenzidine. Preparations were lightly counterstained in
Harris’s haematoxylin, dehydrated, and mounted in Permount
(Fisher Scientific, Pittsburgh, PA, USA). Morphologically pre-
served TUNEL-positive cells and apoptotic bodies were referred to
as apoptotic cells and determined by using predefined measure-
ments in the computer-assisted image analyser in conjunction with
careful evaluation of morphologic criteria.
Quantitative Assessment of Colon Sections
Quantitative analysis of tissue sections (under light microscopy)
was carried out using a computer-assisted image analyser (Leica
QWin Plus V 3.5.1, Leica Microsystems Ltd, Switzerland). The
density of collagen fibres was defined by the area positively stained
for collagen in relation to total intestinal tissue per millimetre-
squared using an imaging analysis system at (6100 magnification).
Percentages of apoptotic cells were defined by the number of
immunoreactive cells in relation to total cells (immunoreactive and
non-immunoreactive cells; 6400 magnification) in the lamina
propria per millimetre squared (counted in at least 10 different
areas), or in at least 500 epithelial cells in the crypts and in the
surface epithelium of longitudinally sectioned colonic crypts. Two
independent observers who were unaware of the experimental
data examined all tissue sections and captured images.
Organ Culture and Cytokine Measurements
Colonic mucosal explants were cultured in RPMI 1640 medium
supplemented with 10% foetal calf serum (Gibco-Invitrogen,
Carlsbad, CA, USA), 2 mM L-glutamine, 50 mM 2-mercaptoeth-
anol, 10 mM HEPES, penicillin (100 killiunits/litre) and strepto-
mycin (100 mg/litre) (all from Sigma Chemical Co., St. Louis,
MO, USA) for 24 h at 37uC in a 5% CO2 humidified incubator.
Samples were centrifuged and the supernatants used for
measurement of the concentration of cytokines TNF-a, IL-1b
(both from Peprotech Inc., Rocky Hill, NJ, USA), VEGF and
TGF-b (R&D Systems, MN, USA), and IL-10 (Invitrogen,
Camarillo, CA, USA) by commercial sensitive enzyme-linked
immunosorbent assays (ELISA) method. The total protein content
of the biopsy specimens was estimated by the PierceH BCA protein
assay kit (Thermo Scientific, Rockford, IL, USA), and used for
normalizing the results. The minimum detectable concentration of
rat TNF-a, IL-1b, VEGF, TGF-b, and IL-10 was less than
5.0 pg/mL.
MSCs Labelling and Imaging
For cell migration studies in vivo, AT-MSCs, BM-MSCs, and
skin fibroblasts were labelled with Tc-99m or stained with CM-DiI
before injection on day 4, and traced for up to 72 hours thereafter.
Briefly, for each animal 2610
6 cells (0.3 mL) were labelled with
Tc-99m based on previously published protocols [58,59] under
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cell suspension in 0.9% NaCl, and the mixture was incubated at
room temperature for 10 min. Then, 5 mCi Tc-99m (1 mL) was
added and the incubation continued for another 10 min. After
centrifugation (5006g for 5 min), the supernatant was removed
and cells were washed again and resuspended in saline solution.
Viability of the labelled cells was assessed by the trypan blue
exclusion test and estimated to be greater than 93% in all cases.
Labelling efficiency was calculated by the activity in the pellet
divided by the sum of the radioactivity in the pellet plus
supernatant, and was estimated to be greater than 90% in all
cases. Tc-99m-labeled cells were then injected intraperitoneally or
intravenously through the jugular vein. Labelled cells were
followed-up with scintigraphic images taken at 30 min, 2 and
24 h after injection at a dual head gamma-camera equipped with
two high-resolution collimators (Millennium MG General Electric
Medical Systems, Milwaukee, WI). Animals were sacrificed under
anaesthesia and bowels were scanned and counted at a Perkin-
Elmer Packard Cobra II Auto Gamma-counter. Representative
images were obtained and analyzed.
In another set of experiments, MSCs were stained with the
fluorescent Cell Tracker
TM CM-DiI (indocarbocyanine) (Invitro-
gen, Carlsbad, CA). Briefly, monolayers were incubated with
2 mg/mL of CM-DiI in DMEM with 10% FBS at 37uC for
5 minutes followed by 15 minutes at 4uC. Cells were then washed
with PBS and trypsinized. For assessing tissue distribution of CM-
DiI-labeled MSCs, 2610
6 cells were injected into the peritoneal
cavity on day 4. Skin fibroblasts used as additional controls did not
migrate into the inflamed colon (data not shown). Seventy-two
hours after cells administration, the left colon was surgically
removed and tissue samples were embedded in resin and snap-
frozen in isopentane in a liquid nitrogen bath. Samples were stored
at 280uC until processing, and then cut into 6-mm section in a
cryostat maintained at 220uC. Tissue sections were air-dried,
fixed for 5 min in 1% paraformaldehyde, and mounted in an
antifading medium containing DAPI. Slides were analyzed with a
Leica TCS-SP5 AOBS confocal laser scanning microscope for
capturing representative images of each sample.
Statistical Analysis
Statistical analyses were performed using the statistical software
SPSS for Windows (Version 10.1, SPSS Inc., 1989–1999, USA).
Statistical differences among the experimental groups were
evaluated with the one-way ANOVA on ranks test in which pair
wise multiple comparisons were carried out using the Dunnett’s
T3 test. Colonoscopic scores and body weight changes before and
after treatment were compared by the Wilcoxon matched-pair
signed rank test. Survival was analyzed by the Kaplan–Meier log-
rank test. The level of significance was set at p,0.05.
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